Acquired Resistance to Crizotinib from a Mutation in CD74–ROS1

Crizotinib, an inhibitor of anaplastic lymphoma kinase (ALK), has also recently shown efficacy in the treatment of lung cancers with ROS1 translocations. Resistance to crizotinib developed in a patient with metastatic lung adenocarcinoma harboring a CD74–ROS1 rearrangement who had initially shown a...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Awad, Mark M., Katayama, Ryohei, McTigue, Michele, Liu, Wei, Deng, Ya-Li, Brooun, Alexei, Friboulet, Luc, Huang, Donghui, Falk, Matthew D., Timofeevski, Sergei, Wilner, Keith D., Lockerman, Elizabeth L., Khan, Tahsin M., Mahmood, Sidra, Gainor, Justin F., Digumarthy, Subba R., Stone, James R., Mino-Kenudson, Mari, Christensen, James G., Iafrate, A. John, Engelman, Jeffrey A., Shaw, Alice T.
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2013
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3878821/
https://ncbi.nlm.nih.gov/pubmed/23724914
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1215530
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge